Biomarker Testing and Clinical Trial Matching: What Patients Should Know
Two people with cancer in the same organ may have tumors with important biological differences. Biomarker testing looks for features in cancer cells, blood, or other samples that may help describe the disease. In some situations, a result can inform treatment planning or identify a clinical trial designed for tumors with a particular molecular characteristic.
Biomarker testing is a powerful tool, but it is not a simple matching service. A finding may be important, uncertain, unrelated to an available option, or only one part of a much larger eligibility review.
Key Takeaways
- Biomarkers are measurable features that can provide information about a cancer or a person's biology.
- Testing may use tumor tissue, blood, or other samples; the appropriate method depends on the clinical question.
- A molecular finding does not automatically mean that a targeted treatment will work or that a trial is available.
- Clinical trial eligibility also depends on diagnosis, disease status, previous treatment, organ function, medications, timing, and protocol-specific rules.
- Results should be interpreted by qualified clinicians in the context of the full medical record.
What is a biomarker?
A biomarker is a biological characteristic that can be measured. In oncology, biomarkers may include gene variants, changes in the number or structure of genes, proteins on or within cells, patterns of gene activity, or broader features such as microsatellite instability or tumor mutational burden.
Some biomarkers help clarify diagnosis or prognosis. Others may predict whether a cancer is more or less likely to respond to a specific approach. A trial may use a biomarker to select participants, assign a treatment group, or study why different tumors respond differently.
Tumor biomarkers and inherited findings are not the same
Tumor, or somatic, testing examines changes found in cancer cells. These changes may have developed during a person's lifetime and may be limited to the tumor. Germline testing looks for inherited variants present in the body's cells and can have implications for the patient and biological relatives.
Sometimes tumor testing raises the possibility of an inherited finding, but it does not always answer that question. A clinician or genetics professional can explain whether confirmatory germline testing and genetic counseling should be considered. Patients should not assume that every alteration in a tumor report is inherited.
How testing is performed
Testing may use archived tissue from a prior biopsy or surgery, a new biopsy, or a blood sample sometimes called a liquid biopsy. Each approach has strengths and limitations. Tissue may provide information from the sampled tumor area, while blood-based testing depends in part on how much tumor material is circulating. A negative result can mean that a target was not found, but it can also reflect sample quality, assay limits, or tumor biology.
Different laboratories test different genes and use different methods. Reports may classify findings as actionable, potentially actionable, of uncertain significance, or not currently linked to a known therapy. Those labels require context and can change as evidence develops.
How biomarkers can shape a clinical trial search
A biomarker-selected trial may require a specific alteration and an approved testing method. Some protocols require confirmation by a central laboratory even when a patient already has a commercial report. Other trials study patients regardless of biomarker status but analyze samples to understand treatment response.
An apparently relevant result is only one layer of matching. The study may also require a certain cancer type, treatment history, measurable disease, performance status, laboratory values, or washout period. Cohorts for a particular biomarker may open, pause, or close.
Questions to ask about a biomarker report
- •What sample was tested, and when was it collected?
- •Was this tumor testing, inherited testing, or both?
- •Which findings are clinically meaningful for my diagnosis?
- •Is the evidence based on an approved treatment, an off-label use, or a clinical trial?
- •Does a potential trial require central confirmation or a new biopsy?
- •Could the result affect relatives, and should I speak with a genetics professional?
- •Would repeating or expanding testing add useful information?
What biomarker testing cannot promise
Testing may not find a target. A target may exist without an available study nearby. A matched investigational treatment may not be safe or effective for a particular person. Even when a trial is scientifically relevant, the patient may not meet other criteria. These limitations should not minimize the value of testing; they help set realistic expectations and support careful interpretation.
How our FCTG team can help
For studies that use molecular eligibility, our FCTG research team may review available pathology and biomarker reports as part of an initial clinical trial review. Our physician investigators evaluate those findings in the context of the diagnosis, prior treatment, and protocol requirements, while our research professionals may request additional records or protocol-required confirmation. This review does not guarantee a match, eligibility, or enrollment.
Interested in evaluating clinical trial options?
Our medical research team can help review available oncology research options.
Trusted Sources & Further Reading
The information provided by Florida Clinical Trials Group is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical trial availability and eligibility vary by study and participant. Submission of information or completion of an initial review does not guarantee eligibility, enrollment, access to an investigational treatment, safety, or benefit. Patients should discuss all medical care and clinical trial decisions with their treating physician and the qualified research team.
